Acceleron Pharma Inc (NASDAQ:XLRN) Short Interest Decreased By 0.07%

June 15, 2018 - By Michael Collier

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

Investors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It improved, as 13 investors sold Acceleron Pharma Inc. shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported.
Numerixs Inv Technologies reported 1,000 shares. Jane Street Group Limited stated it has 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Teacher Retirement System Of Texas holds 8,494 shares. Barclays Plc stated it has 28,105 shares or 0% of all its holdings. Royal Bancshares Of Canada holds 32 shares. Franklin Resources reported 435,577 shares stake. Credit Suisse Ag has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). California Employees Retirement Sys owns 21,300 shares or 0% of their US portfolio. 38,809 were reported by Citigroup. Northern Trust holds 0% or 437,397 shares. Dupont Capital Mngmt Corp has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 4,811 shares. Foresite Cap Management Ii Lc accumulated 3.18% or 244,756 shares. Blackrock holds 0.01% or 4.03M shares. Us Natl Bank De owns 500 shares. Evercore Wealth Ltd has invested 0.05% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Since January 2, 2018, it had 0 insider buys, and 12 sales for $4.08 million activity. Quisel John D had sold 4,333 shares worth $183,806 on Tuesday, January 2. On Tuesday, April 3 Kumar Ravindra sold $46,205 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 1,203 shares. 3,500 shares were sold by Rovaldi Christopher, worth $134,395 on Tuesday, April 3. Sherman Matthew L sold $197,868 worth of stock. On Tuesday, March 6 POPS RICHARD F sold $1.55 million worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 37,500 shares.

The stock of Acceleron Pharma Inc (NASDAQ:XLRN) registered a decrease of 0.07% in short interest. XLRN’s total short interest was 2.73M shares in June as published by FINRA. Its down 0.07% from 2.73M shares, reported previously. With 280,800 shares average volume, it will take short sellers 10 days to cover their XLRN’s short positions. The short interest to Acceleron Pharma Inc’s float is 7.08%.

The stock decreased 0.28% or $0.1 during the last trading session, reaching $36.02. About 257,309 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since June 15, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.65 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The company??s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Acceleron Pharma had 7 analyst reports since January 8, 2018 according to SRatingsIntel. On Monday, January 8 the stock rating was initiated by H.C. Wainwright with “Buy”. H.C. Wainwright initiated Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Wednesday, March 28. H.C. Wainwright has “Buy” rating and $6200 target. Oppenheimer initiated the shares of XLRN in report on Tuesday, May 22 with “Hold” rating. H.C. Wainwright maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Wednesday, February 28. H.C. Wainwright has “Buy” rating and $62.0 target. The firm has “Overweight” rating given on Monday, February 26 by JP Morgan. The firm has “Buy” rating given on Thursday, March 1 by Citigroup. The firm has “Overweight” rating given on Wednesday, February 28 by Barclays Capital.

More important recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: which released: “Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23” on June 15, 2018, also published article titled: “Acceleron: Luspatercept New Data Is A Buy Signal”, published: “Acceleron Pharma (XLRN) Highlights Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia” on June 15, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) was released by: and their article: “Big News Is Fast Approaching for Celgene” with publication date: June 08, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: